A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders
- PMID:16190799
- DOI: 10.1089/cap.2005.15.682
A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders
Abstract
Objective: The aim of this study was to study valproate efficacy and safety for aggression in children and adolescents with pervasive developmental disorders (PDD).
Methods: In this prospective double-blind, placebo-controlled study, 30 subjects (20 boys, 10 girls) 6-20 years of age with PDD and significant aggression were randomized and received treatment with valproate (VPA) or placebo (PBO) for 8 weeks as outpatients. Mean VPA trough blood levels were 75.5 mcg/mL at week 4 and 77.8 mcg/mL at week 8.
Results: No treatment difference was observed statistically between VPA and PBO groups. The Aberrant Behavior Checklist--Community Scale (ABC-C) Irritability subscale was the primary outcome measure (p = 0.65), and CGI--Improvement (p = 0.16) and OAS (p = 0.96) were secondary outcome measures. Increased appetite and skin rash were significant side effects. Only 1 subject was dropped from the study owing to side effects, notably a spreading skin rash, which then resolved spontaneously. Two subjects receiving VPA developed increased serum ammonia levels, one with an associated parent report of slurred speech and mild cognitive slowing. Poststudy, of 16 VPA and PBO subjects receiving VPA, 10 subjects demonstrated sustained response, 4 of whom later attempted taper, with significant relapse of aggression.
Conclusion: The present negative findings cannot be viewed as conclusive, partly owing to the large placebo response, subject heterogeneity, and size of the groups. Larger studies are needed to expand upon these findings.
Similar articles
- The overt aggression scale for rating aggression in outpatient youth with autistic disorder: preliminary findings.Hellings JA, Nickel EJ, Weckbaugh M, McCarter K, Mosier M, Schroeder SR.Hellings JA, et al.J Neuropsychiatry Clin Neurosci. 2005 Winter;17(1):29-35. doi: 10.1176/jnp.17.1.29.J Neuropsychiatry Clin Neurosci. 2005.PMID:15746480Clinical Trial.
- Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.Wake R, Miyaoka T, Inagaki T, Furuya M, Ieda M, Liaury K, Kishi K, Horiguchi J.Wake R, et al.J Child Adolesc Psychopharmacol. 2013 Jun;23(5):329-36. doi: 10.1089/cap.2012.0108.J Child Adolesc Psychopharmacol. 2013.PMID:23782127Clinical Trial.
- Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F.Shea S, et al.Pediatrics. 2004 Nov;114(5):e634-41. doi: 10.1542/peds.2003-0264-F. Epub 2004 Oct 18.Pediatrics. 2004.PMID:15492353Clinical Trial.
- Pharmacotherapy of irritability in pervasive developmental disorders.Stigler KA, McDougle CJ.Stigler KA, et al.Child Adolesc Psychiatr Clin N Am. 2008 Oct;17(4):739-52, vii-viii. doi: 10.1016/j.chc.2008.06.002.Child Adolesc Psychiatr Clin N Am. 2008.PMID:18775367Review.
- Managing irritability and aggression in autism spectrum disorders in children and adolescents.Robb AS.Robb AS.Dev Disabil Res Rev. 2010;16(3):258-64. doi: 10.1002/ddrr.118.Dev Disabil Res Rev. 2010.PMID:20981764Review.
Cited by
- Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents.Stepanova E, Dowling S, Phelps M, Findling RL.Stepanova E, et al.Dialogues Clin Neurosci. 2017 Dec;19(4):395-402. doi: 10.31887/DCNS.2017.19.4/rfindling.Dialogues Clin Neurosci. 2017.PMID:29398934Free PMC article.Review.
- Clinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD).Genovese A, Butler MG.Genovese A, et al.Int J Mol Sci. 2020 Jul 2;21(13):4726. doi: 10.3390/ijms21134726.Int J Mol Sci. 2020.PMID:32630718Free PMC article.Review.
- Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options.Dell'Osso L, Bonelli C, Giovannoni F, Poli F, Anastasio L, Cerofolini G, Nardi B, Cremone IM, Pini S, Carpita B.Dell'Osso L, et al.Pharmaceuticals (Basel). 2025 Feb 25;18(3):324. doi: 10.3390/ph18030324.Pharmaceuticals (Basel). 2025.PMID:40143102Free PMC article.Review.
- Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities.Bahji A, Forth E, Nasar A, Waqas A, Hawken ER, Ayub M.Bahji A, et al.J Psychopharmacol. 2025 Mar;39(3):201-213. doi: 10.1177/02698811241303654. Epub 2024 Dec 17.J Psychopharmacol. 2025.PMID:39690490Free PMC article.Review.
- Chloride imbalance in Fragile X syndrome.Miles KD, Doll CA.Miles KD, et al.Front Neurosci. 2022 Oct 12;16:1008393. doi: 10.3389/fnins.2022.1008393. eCollection 2022.Front Neurosci. 2022.PMID:36312023Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources